Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAL in Obstructive Sleep Apnea Patients
2023-508445-40-00Phase 2Completed
- Sponsor
- SMB Laboratoires
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS) comparing NACYSTELYN with Placebo (2 arms). Primary endpoint: Mean change in Apnea-Hypopnea Index (PSG-AHI3%) from baseline to 6 weeks of treatment. Started May 2024; status: completed.
02
Drugs
nacystelyn
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2023-508445-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508445-40-00.